For decades, the landscape of clinical research was dominated by fixed, traditional trial designs. In these legacy studies, the primary objective was often maintaining a strict, unchanging protocol from inception to conclusion. But the landscape of modern medicine has...
The summer months at the United States Food and Drug Administration are typically among the busiest on the regulatory calendar, and 2026 is proving no exception. With a succession of high-profile FDA drug approval decisions concentrated in June and July 2026, the...
When Brian Wolpin, Professor of Medicine at Harvard Medical School and Director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, advanced to the next slide during the plenary session at the 2026 ASCO (American Society of...
Akeso and Summit Therapeutics’ ivonescimab plus chemotherapy delivers a statistically significant overall survival benefit over a PD-1 inhibitor plus chemotherapy control in the Phase 3 HARMONi-6 trial for previously untreated advanced squamous non-small cell lung...
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held from 29 May to 2 June in Chicago, drew more than 44,000 oncology professionals and delivered what many clinicians described as some of the most consequential trial data seen at the conference...
Landmark clinical trial results expected in 2026 as disease-modifying Parkinson’s pipeline reaches critical phase Medical research charity Cure Parkinson’s says the Parkinson’s research field is approaching a pivotal moment, as a wave of results from clinical trials...
Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...
AstraZeneca's eneboparatide meets the Phase 3 CALYPSO primary endpoint in chronic hypoparathyroidism with full data presented at the European Congress of Endocrinology, Alkermes' LUMRYZ meets its primary endpoint in the Phase 3 REVITALYZ trial for idiopathic...
Alzheimer’s disease (AD) represents a significant medical concern for all of us as we grow older, as the NIH has published that the average risk of dementia over 55 years old is now 42%. AD is presently affecting 6.9 million Americans aged 65 or older and is expected...
Cytokinetics’ aficamten meets dual primary endpoints in the pivotal Phase 3 ACACIA-HCM trial for non-obstructive hypertrophic cardiomyopathy, Axsome Therapeutics secures FDA approval of AUVELITY as the first non-antipsychotic treatment for Alzheimer’s disease...
Children have long been described as therapeutic orphans. It is a term first used by the American paediatrician Harry Shirkey of the Children’s Hospital in Birmingham, Alabama, at a 1963 conference and formally published in 1968. Despite more than five decades of...
For decades, clinical trials have failed to adequately represent the patients who will ultimately use the medicines and treatments being tested. Gaps in enrolment across race, ethnicity, sex, age, and socioeconomic background have created an incomplete evidence base,...
Etavopivat delivers Phase 3 success in sickle cell disease, satralizumab becomes the first positive Phase 3 result in MOGAD, AstraZeneca completes its triple-positive COPD biologic programme, and a busy week for paediatric medicine brings new approvals and data in...
Speech is rapidly emerging as an important, non-invasive, digital clinical marker in neurodegenerative disease research, according to leading biotech SynaptixBio. The company has facilitated a study run by Australia-based speech analytics company Redenlab, in...
Most Supplement Companies Skip the RCT. Here’s Why the Few That Don’t Often Get It Wrong The industry’s uncomfortable truth The global dietary supplement market is worth hundreds of billions of dollars.[1] Brands make claims about energy, cognition, immunity, and...
Neurona Therapeutics' rezanecel demonstrates durable seizure reduction past the one-year mark in drug-resistant mesial temporal lobe epilepsy at the AAN Annual Meeting, Gilead Sciences and Arcus Biosciences' TIGIT inhibitor domvanalimab fails its pivotal Phase 3 lung...
Panthera Biopartners Expands European Footprint with Acquisition of Hungary’s Leading Clinical Research Organisation, OEC Strategic acquisition marks the first step in Panthera’s European expansion, strengthening its global competitiveness Panthera Biopartners...
Revolution Medicines' daraxonrasib nearly doubles overall survival in previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial, Travere Therapeutics' Filspari receives FDA approval as the first-ever treatment for focal segmental...